Table 2.

Time-Dependent Competing Risk Regression Analysis for Waitlist Mortality

	Univariable			Multivariable*
	SHR	95% CI	p-value	SHR	95% CI	p-value
Renal Group
Normal	-	-	-	-	-	-
AKI	3.25	3.00 – 3.52	<0.001	2.42	2.22 – 2.64	<0.001
CKD	1.82	1.70 – 1.95	<0.001	1.56	1.45 – 1.67	<0.001
AKI on CKD	4.03	3.75 0 4.34	<0.001	2.86	2.65 – 3.10	<0.001
Age per Year	1.02	1.02 – 1.03	<0.001	1.02	1.02 – 1.03	<0.001
Female Sex	1.09	1.04 – 1.15	<0.001	1.11	1.05 – 1.18	<0.001
Etiology
Alcohol	-	-	-	-	-	-
HCV	1.22	1.14 – 1.31	<0.001	1.03	0.95 – 1.11	0.48
NASH	1.17	1.09 – 1.27	<0.001	0.93	0.85 – 1.02	0.13
Autoimmune1	0.88	0.81 – 0.97	0.006	0.85	0.76 – 0.94	0.002
Other	0.96	0.85 – 1.08	0.48	1.01	0.88 0 1.16	0.85
Non-Hispanic White	0.94	0.89 – 0.99	0.02
BMI per 1 kg/m2	1.00	1.00 – 1.01	0.08	0.99	0.98 – 0.99	<0.001
Ascites	1.56	1.48 – 1.63	<0.001	0.86	0.81 – 0.92	<0.001
HE	2.80	2.65 – 2.96	<0.001	1.91	1.79 – 2.05	<0.001
Diabetes Mellitus	1.30	1.23 – 1.37	<0.001	1.09	1.02 – 1.17	0.007
KPS at last follow-up per 10 points	0.94	0.93 – 0.95	<0.001
Ventilator Use at Last Follow-Up	0.96	0.55 – 1.67	0.88
Final MELDNa per point	1.05	1.05 – 1.06	<0.001	1.03	1.02 – 1.04	<0.001
Final Albumin per 1g/dL	0.63	0.61 – 0.66	<0.001	0.68	0.65 – 0.70	<0.001

¹Combined Autoimmune Hepatitis, Primary Sclerosing Cholangitis, and Primary Biliary Cholangitis; Hepatitis C (HCV); Non-Alcoholic Steatohepatitis (NASH); Body Mass Index (BMI); Hepatic Encephalopathy (HE); Karnofosky Performance Score (KPS); Model for End-Stage Liver Disease with Serum Sodium (MELDNa);

^*adjusted for region and blood type